E2F1 apoptosis counterattacked: evil strikes back
Authors:
- Brigitte M. PützerBrigitte M. Pützer
- David EngelmannDEDavid Engelmann
- 1 February 2013
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 19 (2) , 89-98
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progressionJournal of Clinical Investigation, 2010
- Translating DNA damage into cancer cell death—A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistanceDrug Resistance Updates, 2010
- Expression Signature of E2F1 and Its Associated Genes Predict Superficial to Invasive Progression of Bladder TumorsJournal of Clinical Oncology, 2010
- E2F1 in Melanoma Progression and MetastasisJNCI: Journal of the National Cancer Institute, 2010
- Emerging roles of E2Fs in cancer: an exit from cell cycle controlNature Reviews Cancer, 2009
- E2F1 Expression Predicts Outcome in Korean Women Who Undergo Surgery for Breast CarcinomaAnnals of Surgical Oncology, 2009
- Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation TherapyClinical Cancer Research, 2008
- E2F1-induced apoptosis: turning killers into therapeuticsTrends in Molecular Medicine, 2006
- Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinomaJournal of Cancer Research and Clinical Oncology, 2004
- E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and CyclophosphamideBreast Cancer Research and Treatment, 2003